CytomX Therapeutics, Inc. (CTMX)
CytomX Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer treatments using its proprietary Probody technology. This platform employs antibody masks that remain inactive until they reach the tumor site, aiming to improve safety and efficacy by reducing off-target effects. Founded in 2011 and based in South San Francisco, CytomX collaborates with various pharmaceutical partners to advance immuno-oncology and targeted cancer therapies.
Company News
CytomX Therapeutics reported Q2 2025 results with declining revenue, reduced operating expenses, and positive clinical pipeline progress, particularly for its lead colorectal cancer candidate CX-2051.
Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.
CytomX Therapeutics and Moderna presented preclinical data on an mRNA-encoded masked IL-12 molecule, which showed potent anti-tumor activity with enhanced tolerability.
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's 3 data points you should be using when buying and selling penny stocks The post What Data Points Should You Use to Trade Penny Stocks? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.